Altimmune
ALTALT · Stock Price
Historical price data
Overview
Altimmune's mission is to develop transformative peptide-based medicines for obesity, liver diseases, and other metabolic disorders. Its strategic pivot from vaccines to metabolic therapeutics is anchored by compelling Phase 2 data for pemvidutide, which showed significant weight loss and resolution of metabolic dysfunction-associated steatohepatitis (MASH). The company's strategy focuses on advancing pemvidutide into late-stage development while leveraging its peptide engineering platform to build a pipeline of targeted multi-agonists.
Technology Platform
Proprietary peptide engineering platform designed to create single-molecule, multi-targeted agonists (e.g., GLP-1/glucagon) with optimized pharmacokinetics and hepato-directed targeting for metabolic diseases.
Pipeline
19| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Licensed seasonal influenza vaccine | Influenza | Approved | |
| NasoVAX | Influenza | Phase 2 | |
| Pemvidutide + Placebo | Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | |
| Pemvidutide | Alcohol Use Disorder (AUD) | Phase 2 | |
| Pemvidutide | Alcohol Liver Disease | Phase 2 |
Opportunities
Risk Factors
Competitive Landscape
Altimmune competes in obesity against dominant GLP-1 products (Novo Nordisk, Eli Lilly) and next-generation multi-agonists, and in MASH against newly approved Madrigal's resmetirom and other late-stage candidates. Differentiation hinges on pemvidutide's balanced dual-agonist profile and hepato-directed action.